



## Expanded Access Policy

### Obtaining pre-approval access to investigational drugs developed by JCR Pharmaceuticals

As a pioneering company in the field of research, development, manufacturing, and marketing of biopharmaceuticals and regenerative medicine, JCR Pharmaceuticals aims to contribute to global health by offering better treatment options. We use advanced biotechnology to address serious and life-threatening inherited disorders, including lysosomal storage diseases, neurometabolic disorders, graft-versus-host disease (GVHD) in patients who have undergone hematopoietic stem cell transplantation (HSCT), and growth hormone deficit disorders. Because people living with these debilitating life-threatening conditions have few or no treatment options, our work is marked not only by a commitment to the highest standards of preclinical and clinical research but also by an acute sense of urgency for obtaining regulatory approval.

### Our commitment to clinical research

To ensure that patients have the chance to benefit from these potentially transformative drugs, we focus resources on conducting clinical trials which meet the exacting standards of regulatory authorities around the world and on obtaining their approval. We believe that quick regulatory approval is the best way to ensure timely access by patients to our medications. Therefore, JCR will prioritize clinical studies and will not allow access of an experimental drug prior regulatory approval." If you have any questions please talk to your physician or contact us on [med\\_info@jp.icrpharm.com](mailto:med_info@jp.icrpharm.com)

*JCR Pharmaceuticals reserves the right to revise this policy at any time.*